Go to JCI Insight
Jci spelled out white on transparent.20160208
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews...
    • Biology of familial cancer predisposition syndromes (Feb 2019)
    • Mitochondrial dysfunction in disease (Aug 2018)
    • Lipid mediators of disease (Jul 2018)
    • Cellular senescence in human disease (Apr 2018)
    • Fibrosis (Jan 2018)
    • Glia and Neurodegeneration (Sep 2017)
    • Transplantation (Jun 2017)
    • View all review series...
  • Collections
    • Recently published
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Scientific Show Stoppers
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

Jci only white

  • About
  • Editors
  • Consulting Editors
  • For authors
  • Current issue
  • Past issues
  • By specialty
  • Subscribe
  • Alerts
  • Advertise
  • Contact
  • Conversations with Giants in Medicine
  • Author's Takes
  • Recently published
  • Brief Reports
  • Technical Advances
  • Commentaries
  • Editorials
  • Hindsight
  • Review series
  • Reviews
  • The Attending Physician
  • First Author Perspectives
  • Scientific Show Stoppers
  • Top read articles
  • Concise Communication
Senescent cells: a therapeutic target for cardiovascular disease
Bennett G. Childs, … , Hu Li, Jan M. van Deursen
Bennett G. Childs, … , Hu Li, Jan M. van Deursen
Published April 2, 2018
Citation Information: J Clin Invest. 2018;128(4):1217-1228. https://doi.org/10.1172/JCI95146.
View: Text | PDF
Category: Review Series

Senescent cells: a therapeutic target for cardiovascular disease

  • Text
  • PDF
Abstract

Cellular senescence, a major tumor-suppressive cell fate, has emerged from humble beginnings as an in vitro phenomenon into recognition as a fundamental mechanism of aging. In the process, senescent cells have attracted attention as a therapeutic target for age-related diseases, including cardiovascular disease (CVD), the leading cause of morbidity and mortality in the elderly. Given the aging global population and the inadequacy of current medical management, attenuating the health care burden of CVD would be transformative to clinical practice. Here, we review the evidence that cellular senescence drives CVD in a bimodal fashion by both priming the aged cardiovascular system for disease and driving established disease forward. Hence, the growing field of senotherapy (neutralizing senescent cells for therapeutic benefit) is poised to contribute to both prevention and treatment of CVD.

Authors

Bennett G. Childs, Hu Li, Jan M. van Deursen

×

Figure 1

Key properties of senescent cells.

Options: View larger image (or click on image) Download as PowerPoint
Key properties of senescent cells.
In response to various types of stres...
In response to various types of stressors (generally irreparable macromolecular damage), replication-competent cardiovascular cells undergo senescence. The 3 major hallmarks of SNCs are a permanent cell cycle arrest, mediated by signaling through the p19Arf-p53-p21Cip/Waf and p16Ink4a-Rb axes; apoptosis resistance, achieved by upregulation of prosurvival factors; and acquisition of the senescence-associated secretory phenotype (SASP), a bioactive secretome containing cytokines, growth factors, proteases, and other signaling molecules.
Follow JCI: Facebook logo white Twitter logo v2 Rss icon
Copyright © 2019 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts